Biotech & Life Sciences

  • Sanofi’s Amlitelimab Clears Regulatory Bar, Raises New Investor Doubts

    Sanofi’s Amlitelimab Clears Regulatory Bar, Raises New Investor Doubts

    SNY performance by TradingView Sanofi (NASDAQ: SNY, Euronext Paris: SAN)’s amlitelimab still looks like a viable U.S. approval candidate, but it is no longer the clear successor to Dupixent that investors once hoped for. The latest data keeps the program alive from a regulatory standpoint, yet introduces enough uncertainty that the stock is unlikely to

    read more

  • Experienced Biotech Executives Launch New Rare Disease Startup

    Experienced Biotech Executives Launch New Rare Disease Startup

    Another rare disease startup is entering the market, this time backed by a group of executives who have been here before. Mendra, a new biotech led by former BioMarin and Escient Pharmaceuticals executives, has raised $82 million in a Series A round led by OrbiMed, 8VC, and 5AM Ventures. The company says the capital will

    read more

  • China Becomes New Hunting Ground for Obesity Drugs

    China Becomes New Hunting Ground for Obesity Drugs

    Corxel’s latest funding round lands at a time when U.S. and European drug developers are increasingly sourcing new medicines from China. Over the past few years, both large pharmaceutical companies and venture-backed biotech firms have shown a willingness to license compounds discovered in Chinese labs and move them quickly into Western clinical programs. That strategy

    read more

  • New Study Shows Brain Processes Language Like AI Models

    New Study Shows Brain Processes Language Like AI Models

    For years, neuroscientists have debated how people actually make sense of spoken language. Is it driven by strict rules, or does meaning slowly come together as we hear more words? A new study suggests it is the latter. And interestingly, the process looks a lot like how modern AI language models handle text. What the

    read more

  • JNJ Earnings Hit Growth, But Patent Losses Threaten Future Sales

    JNJ Earnings Hit Growth, But Patent Losses Threaten Future Sales

    Johnson & Johnson (NYSE: JNJ) shares fell about 1 percent in early Wednesday trading as investors digested the company’s latest earnings report. Management highlighted confidence in the business, with CEO Joaquin Duato calling the company’s lineup the strongest it has ever had. The market response suggested lingering doubts. Concerns remain around patent losses, litigation exposure,

    read more

  • Corvus’ Experimental Drug Delivers Strong Results in Hard-to-Treat AD

    Corvus’ Experimental Drug Delivers Strong Results in Hard-to-Treat AD

    Corvus Pharmaceuticals (NASDAQ: CRVS) announced encouraging results from cohort 4 of its Phase 1 trial of soquelitinib in moderate to severe atopic dermatitis. The data show good safety and efficacy, similar to earlier cohorts, and suggest longer treatment may improve responses. Cohort 4 Results Cohort 4 included 12 patients on soquelitinib and 12 on placebo.

    read more

  • The Hidden Investing Risk No One Talks About: Cognitive Decline

    The Hidden Investing Risk No One Talks About: Cognitive Decline

    Investors spend a lot of time debating valuations, interest rates, and where the next recession might come from. Very little time is spent on something that is arguably just as important over the long run: whether we remain capable of making good financial decisions as we age. That is not a comfortable topic. It also

    read more

  • Breakthrough: Atossa’s (Z)-Endoxifen Gains FDA Orphan Status for DMD

    Breakthrough: Atossa’s (Z)-Endoxifen Gains FDA Orphan Status for DMD

    Atossa Therapeutics (Nasdaq: ATOS) said the FDA granted Orphan Drug Designation for its drug (Z)-endoxifen in Duchenne muscular dystrophy. This follows a prior Rare Pediatric Disease designation. It’s a positive regulatory step. But it does not guarantee approval and it does not make trials any faster. CEO Steven Quay called it an important milestone. He

    read more

  • One Dose, Months of Relief: Eupraxia’s EoE Breakthrough

    One Dose, Months of Relief: Eupraxia’s EoE Breakthrough

    Eupraxia Pharmaceuticals (NASDAQ:EPRX) (TSX:EPRX) put out an update on its RESOLVE study this week, and the results look encouraging, at least at this stage. The company shared new tissue and symptom data from patients treated with EP-104GI for eosinophilic esophagitis, a condition that remains difficult to treat long term. What stands out most is how

    read more

  • Chinese Biotech Growth Forces U.S. Companies to Innovate Faster

    Chinese Biotech Growth Forces U.S. Companies to Innovate Faster

    David Li, founder of Meliora Therapeutics, quickly learned that the U.S. biotech space isn’t isolated anymore. While looking at drug targets for his new company, he noticed that a lot of the same targets were already being pursued by Chinese firms. Curious, he went to Shanghai and Suzhou. What he saw surprised him. “They’re all

    read more